Publications by authors named "T P Ready"

At each stage of the HIV life cycle, host cellular proteins are hijacked by the virus to establish and enhance infection. We adapted the virus packageable HIV-CRISPR screening technology at a genome-wide scale to comprehensively identify host factors that affect HIV replication in a human T cell line. Using a smaller, targeted HIV Dependency Factor (HIVDEP) sublibrary, we then performed screens across HIV strains representing different clades and with different biological properties to define which T cell host factors are important across multiple HIV strains.

View Article and Find Full Text PDF

Purpose: To evaluate the impact of FDA's 2013 zolpidem Drug Safety Communications (DSCs), which recommended lowering the initial dose to mitigate drowsiness, on national estimates of zolpidem users and zolpidem exposure cases.

Methods: We analyzed trend changes of national zolpidem users from the IQVIA Total Patient Tracker (TPT) and zolpidem exposure cases reported to the National Poison Data System (NPDS), 2009-2018. To control for time varying confounding, the adjusted trends were analyzed using simple and controlled interrupted time series (ITS).

View Article and Find Full Text PDF

Food insecurity is an ongoing and persistent problem for many individuals and families in the United States and in New York City. The COVID-19 pandemic has exacerbated the scope of the problem and data show that food insecurity rates have increased almost three times over pre-COVID rates. In addition, with unemployment increasing daily and the closure of safety net programs and services, there became a need for creatively attending to the basic needs of individuals and families.

View Article and Find Full Text PDF
Article Synopsis
  • * Between 2001 and 2018, only 19 drugs were withdrawn for safety-related reasons, showing a decline in the number of market withdrawals compared to earlier years; notable heart rhythm issues and liver toxicity were highlighted as gender-specific risks.
  • * The FDA has improved its approach to incorporating sex and gender considerations in drug trials, promoting women's inclusion in research, enhancing safety reviews, and advancing surveillance practices to better protect public health.
View Article and Find Full Text PDF